US-based full service specialty laboratory BioReference Laboratories Inc, an OPKO Health company (NASDAQ:OPK), revealed on Monday that it is participating in the NY Forward Rapid Testing Program and has opened eight locations offering COVID-19 rapid testing in New York, to provide New Yorkers and visitors with inexpensive and rapid COVID-19 testing.

The company said that NY Forward is a collaboration with The Empire State Development Corporation, The Real Estate Board of New York (REBNY), CVS Pharmacy and BioReference, offering rapid COVID-19 specimen collection and testing at locations throughout New York. It added that several hundred additional testing locations are expected to open throughout the State in the near future.

Individuals can schedule a rapid COVID-19 test on mobile devices or computers by visiting https://nyforward.bioreference.com. All individuals must have an appointment and will be asked to pay in advance. Results will be available within approximately 30 minutes or less, which are sent via secure email. This will allow users to show proof of a negative COVID-19 result.

BioReference Laboratories is focused on genetics, oncology, urology and women's health, offering comprehensive test solutions.

OPKO is a multinational biopharmaceutical and diagnostics company.